FierceBiotech Radio on GSK's CEO shakeup, Lilly's Alzheimer's uncertainty, and Valeant's latest disaster

FiercePharma's Eric Palmer and FierceBiotech's Damian Garde discuss the pending retirement of GlaxoSmithKline CEO Andrew Witty, Eli Lilly's bold decision with a big Alzheimer's trial and Valeant Pharmaceuticals' rough week.

Download the episode on iTunes or Stitcher, or listen below--and be sure to subscribe. Let us know what you think by dropping a line to [email protected]

Suggested Articles

The financing sets AM-Pharma up to advance in sepsis-associated acute kidney injury independently now Pfizer has turned down its option to buy.

The FDA sent Eton's partner, Bausch Health, a complete response letter that raised “no concerns” about the clinical data in the drug’s application.

A new partnership will test drug cocktails containing Karyopharm's new product Xpovio in cell samples from glioblastoma patients.